Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer

Jie Chang; Ruirui Yang; Lifan Chen; Zisheng Fan; Jingyi Zhou; Hao Guo; Yinghui Zhang; Yadan Liu; Guizhen Zhou; Keke Zhang; Kaixian Chen; Hualiang Jiang; Mingyue Zheng; Sulin Zhang

doi:10.1016/j.apsb.2022.02.011

Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer

Acta Pharm Sin B. 2022 May;12(5):2619-2622. doi: 10.1016/j.apsb.2022.02.011. Epub 2022 Feb 16.

Authors

Jie Chang^{1

2}, Ruirui Yang^{2

3

4}, Lifan Chen^{2

3}, Zisheng Fan^{1

2}, Jingyi Zhou^{1

2}, Hao Guo^{2

3}, Yinghui Zhang^{2

3}, Yadan Liu^{1

2}, Guizhen Zhou^{1

2}, Keke Zhang^{1

2}, Kaixian Chen^{2

3

1}, Hualiang Jiang^{2

3

1

4}, Mingyue Zheng^{2

3

1}, Sulin Zhang^{2

3}

Affiliations

¹ School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
² Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
³ University of Chinese Academy of Sciences, Beijing 100049, China.
⁴ Shanghai Institute for Advanced Immunochemical Studies, and School of Life Science and Technology, ShanghaiTech University, Shanghai 200031, China.

Abstract

Image 1.

Keywords: ADP-ribosylation factor 1; Breast cancer; Demethylzeylasteral; Virtual screening.